Power3 Medical Products, Inc (PWRME)

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

Breast cancer is a kind of tumor that develops in the cells of a person’s breast. You may think that only women can get breast cancer, but because all people have breast tissue, men can get breast cancer as well though this is very rare.

Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of product NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

Someone with breast cancer may have cancer cells in just one part of the breast, which might be felt as a lump. The cancer can spread throughout one or both breasts. Sometimes breast cancer spreads to other parts of the body, like the bones, the liver, or elsewhere.

BC-SeraPro™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.

For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com

*****************************************

Majestic Gold Corp. (MJS.V)

Majestic Gold Corp. engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.

Gold has a diversity of special properties that make it the most useful of all the minerals mined today. This is because gold conducts electricity and does not tarnish. Gold is very easy to work with and can be drawn into wire. Gold can also be hammered into thin sheets and can be mixed with different metals. The wonderful color of gold leaves a special impression on most people. Gold is used in the industrial field by manufacturers of electronics. Most electronics use very low voltages and currents and can be easily interrupted by corrosion or tarnish at the contact points. Since gold is a highly efficient conductor that can easily carry these low currents without corroding it is used in many things. Gold is used in connectors, switch and relay contacts, soldered joints and connection strips.

Majestic Gold Corp. is pleased to provide a progress update on the new mill construction for the company’s flagship Song Jiagou project.

The mill is in the commissioning stage and has begun running ore through the mill in order to access the efficiency of the mill. Majestic expects to run at an initial throughput rate of 3,000 tonnes per day and progressively move upwards towards full capacity of 6,000 tonnes per day once the mill is running at optimal efficiency.

Ore that has been stockpiled at the new mill in order to streamline the commissioning process is currently being processed as part of the commissioning stage. In addition, Majestic is pleased to announce that the tailings dam is fully completed and all tailings lines and water return systems are in place and now in use.
They are excited by the prospect of getting the new mill on line and being in a position to significantly increase production levels. This represents a significant milestone in their transition from exploration to production.

For more information about Majestic Gold Corp. visit its website: http://www.majesticgold.net

****************************************

Air Methods Corp. (Nasdaq:AIRM) will report financial results for the first quarter ended March 31, 2011 after the close of the market on Thursday, May 5, 2011. The Company has scheduled a conference call for Thursday, May 5, 2011 at 4:15 p.m. Eastern to discuss these results. Interested parties can access the call by dialing (877) 883-0656 (domestic) or (706) 643-8826 (international) or by accessing the web cast at www.airmethods.com. A replay of the call will be available at (800) 642-1687 (domestic) or (706) 645-9291 (international), access number 63074081, for 3 days following the call and the web cast can be accessed at www.airmethods.com for 30 days.

Air Methods Corporation, together with its subsidiaries, provides air medical emergency transport services and systems in the United States. It transports persons requiring intensive medical care from the scene of accident or general care hospitals to highly skilled trauma centers or tertiary care centers.

********************************************

Atlas Air Worldwide Holdings Inc. (Nasdaq:AAWW) a leading global provider of air cargo assets and outsourced aviation operating services and solutions, will release results for the first quarter ended March 31, 2011, prior to the opening of stock market trading on Tuesday, May 3, 2011. William J. Flynn, AAWW’s President and Chief Executive Officer, and Spencer Schwartz, Senior Vice President and Chief Financial Officer, will host a conference call to discuss AAWW’s results at 11:00 a.m. Eastern Time on May 3.

Atlas Air Worldwide Holdings, Inc. provides air cargo and outsourced aircraft operating solutions worldwide. The company operates through four segments: Aircraft, Crew, Maintenance, and Insurance (ACMI); Air Mobility Command (AMC) Charter; Commercial Charter; and Dry Leasing.

****************************************

T. Rowe Price Group, Inc. (Nasdaq:TROW) reported its first quarter 2011 results, including net revenues of $682.4 million, net income of $194.6 million, and diluted earnings per common share of $.72, an increase of 26% from the $.57 per share in the comparable 2010 quarter. Net revenues were $556.2 million in the first quarter of 2010, and net income was $153.0 million. Assets under management increased $27.9 billion from $482.0 billion at December 31, 2010, to a record $509.9 billion at March 31, 2011, including $300.2 billion in the T. Rowe Price mutual funds distributed in the United States and $209.7 billion in other managed investment portfolios. Net cash inflows in the first quarter 2011 totaled $5.8 billion, and market appreciation and income added $22.1 billion to assets under management. As a result, investment advisory revenues increased 25%, or $117 million, from the comparable 2010 quarter. Relative to the 2010 first quarter, investment advisory revenues earned from the T. Rowe Price mutual funds distributed in the U.S. increased 23%, or $75.1 million, to $400.5 million. Average mutual fund assets under management in the first quarter 2011 were $292.0 billion, an increase of 23% from the average for the comparable 2010 quarter. Mutual fund assets at March 31, 2011 were $300.2 billion, an increase of $17.6 billion, or 6%, from the end of 2010. The firm voluntarily waived money market fund fees of $7.0 million in the first quarter 2011 in order to maintain a positive yield for fund investors, compared to fee waivers of $6.8 million in the comparable 2010 quarter.

T. Rowe Price Group, Inc. is a publicly owned asset management holding company. The firm primarily provides its services to individual and institutional investors, retirement plans, and financial intermediaries.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRME.OB).

Global Hunter Corp. (BOB.V)

Global Hunter Corp. engages in the acquisition, exploration, and development of mineral properties in Canada and Chile. It primarily explores for gold, copper, and base and precious metals. The company was founded in 1988 and is headquartered in Vancouver, Canada.

Molybdenum also is an important material for the chemicals and lubricant industries. Molybdenum has uses as catalysts, paint pigments, corrosion inhibitors, smoke and flame retardants, dry lubricant (molybdenum disulfide) on space vehicles and resistant to high loads and temperatures. As a pure metal, molybdenum is used because of its high melting temperatures as filament supports in light bulbs, metal-working dies and furnace parts.

Molybdenum is alloyed with steel making it stronger and more highly resistant to heat because molybdenum has such a high melting temperature. The alloys are used to make such things as rifle barrels and filaments for light bulbs. The iron and steel industries account for more than 75% of molybdenum consumption.

Global Hunter’s Rabbit South molybdenum project is located within a prolific mining region in the Dominic and Roper Lake area, 27 kilometres west-southwest of the city of Kamloops British Columbia. The property is accessible year round by a combination of highway and logging roads. Rabbit South is situated 25 kilometres northeast of Highland Valley, BC’s largest porphyry copper mine (1.4 billion tonnes @ 0.40% Cu) and 12 kilometres southwest of Afton, BC’s richest porphyry copper mine (107Mi tonnes @ 1.05% Cu, 0.70g/t Au).

The area has been the subject of molybdenum exploration dating back to 1960. Between 1979 and 1981 an extensive exploration program including 69 percussion drill holes and 10 diamond drill holes identified the Roper Lake Molybdenum Target. A non-code-complaint resource of 65 million tonnes at 0.065% of Molybdenum was identified in two zones. Zone A measures 600 metres in length and is 300 meters wide by 60 metres deep, while Zone B has been outlined for 500 metres in length, 400 metres in width and 70 metres in depth.

Global Hunter Corp. announced that it recently completed a surface sampling program at La Corona de Cobre. The program was designed to collect surface samples from the numerous prospective shear zones. This would aid in the definition of drill targets to expand on the copper oxide mineralization. The company has collected approximately 250 samples from the shear zones listed below.

The shear zones and areas of alteration that have been sampled (from East to West) include the following zones:
- El Manto.
- La Golondrina.
- Cerro Borracho.
- El Tazon.
- La Copa.
- La Varrilla.
- Et Tazon.
- Vino Fino.
- Abisinia.

The samples have been collected from outcrops along the entire strike lengths of the shears and will be shipped to ALS Chemex Labs in La Serena Chile for analysis.

For more information about Global Hunter Corp please visit http://www.globalhunter.ca

***********************************

Power3 Medical Products, Inc (PWRME)

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

Breast cancer affects one in eight women during their lives. Breast cancer kills more women in the United States than any cancer except lung cancer. No one knows why some women get breast cancer, but there are a number of risk factors. Risks that you cannot change include
Age - the chance of getting breast cancer rises as a woman gets older
Genes - there are two genes, BRCA1 and BRCA2 that greatly increase the risk. Women who have family members with breast or ovarian cancer may wish to be tested.

Personal factors - beginning periods before age 12 or going through menopause after age 55
Other risks include being overweight, using hormone replacement therapy, taking birth control pills, drinking alcohol, not having children or having your first child after age 35 or having dense breasts.

Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of product NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

BC-SeraPro™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.

For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com

******************************************

Henry Schein Inc. (Nasdaq:HSIC) the largest provider of health care products and services to office-based practitioners, announced that it will release its first quarter 2011 financial results before the stock market opens on Tuesday, May 3, 2011, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern Daylight Time. Speakers on the call will include Stanley M. Bergman, Chairman and Chief Executive Officer of Henry Schein, and Steven Paladino, the Company’s Executive Vice President and Chief Financial Officer.

Henry Schein, Inc. distributes healthcare products and services primarily to office-based healthcare practitioners. It operates in two segments, Healthcare Distribution and Technology.

**************************************

Erie Indemnity Co. (Nasdaq:ERIE) will host an audio Webcast with the financial community to discuss financial results for the first quarter 2011 on Friday, May 6, 2011, at 10:00 a.m. Eastern Time. Erie Indemnity will issue a press release reporting its results after the close of the market on Thursday, May 5, 2011. The Webcast will be broadcast live via the Company’s Investor Relations Web site at www.erieinsurance.com, and will be available as an archive after 1:30 p.m. ET. To automatically receive Erie Indemnity financial news by email, please visit www.erieinsurance.com and subscribe to email alerts.

Erie Indemnity Company provides sales, underwriting, and policy issuance services to the policyholders of Erie Insurance Exchange in the United States. The company offers property/casualty insurance; and underwrites personal and commercial lines property, and casualty coverage.

**************************************

Heartware International Inc. (Nasdaq:HTWR) plans to release financial results for the first quarter ended March 31, 2011, after the close of the U.S. stock markets on Thursday, May 5, 2011. A conference call with management is scheduled for 5:00 pm U.S. Eastern Daylight Time on Thursday, May 5, 2011 (being 7:00 am Australian Eastern Standard Time, Friday, May 6, 2011) to discuss the Company’s financial results, highlights from the quarter and business outlook. The call may be accessed by dialing 1-888-846-5003 five minutes prior to the scheduled start time and referencing “HeartWare.” For callers outside the U.S., please dial + 1-480-629-9809.

HeartWare International, Inc., a medical device company, engages in the design, manufacture, and marketing of medical devices for the treatment of advanced heart failure. The company is headquartered in Framingham, Massachusetts.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRME.OB).

Power3 Medical Products, Inc (PWRME)

Alzheimer’s disease (AD) is the most common form of dementia among older people. Dementia is a brain disorder that seriously affects a person’s ability to carry out daily activities.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

Alzheimer’s disease begins slowly. It first involves the parts of the brain that control thought, memory and language. People with AD (Alzheimer’s disease) may have trouble remembering things that happened recently or names of people they know. Over time, symptoms get worse. People may not recognize family members or have trouble speaking, reading or writing. They may forget how to brush their teeth or comb their hair. Later on, they may become anxious or aggressive, or wander away from home. Eventually, they need total care. This can cause great stress for family members who must care for them.
Alzheimer’s disease usually begins after age 60. The risk goes up as you get older. Your risk is also higher if a family member has had the disease.

Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

Power3 Medical is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases. The research platform is centered on the study of proteomics, the science of protein interactions within living cells. With a combined 50+ years of proteomic experience, the Company has identified 334 protein biomarkers with the following potential medical applications:

1) Breast Cancer 5) Chemotherapeutic Drug Resistance
2) Alzheimer’s Disease 6) Leukemia
3) ALS (Lou Gehrig’s Disease) 7) Gastrointestinal Disease
4) Parkinson’s Disease 8)Metabolic Syndrome

For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com

****************************************

Majestic Gold Corp. (MJS.V)

The most important industrial use of gold is in the manufacture of electronics. Solid state electronic devices use very low voltages and currents which are easily interrupted by corrosion or tarnish at the contact points. Gold is the highly efficient conductor that can carry these tiny currents and remain free of corrosion. Electronic components made with gold are highly reliable. Gold is used in connectors, switch and relay contacts, soldered joints, connecting wires and connection strips.

Majestic Gold Corp. engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.

Majestic Gold Corp. is pleased to provide a progress update on the new mill construction for the company’s flagship Song Jiagou project.

The mill is in the commissioning stage and has begun running ore through the mill in order to access the efficiency of the mill. Majestic expects to run at an initial throughput rate of 3,000 tonnes per day and progressively move upwards towards full capacity of 6,000 tonnes per day once the mill is running at optimal efficiency.

Ore that has been stockpiled at the new mill in order to streamline the commissioning process is currently being processed as part of the commissioning stage. In addition, Majestic is pleased to announce that the tailings dam is fully completed and all tailings lines and water return systems are in place and now in use.
They are excited by the prospect of getting the new mill on line and being in a position to significantly increase production levels. This represents a significant milestone in their transition from exploration to production.

For more information about Majestic Gold Corp. visit its website: http://www.majesticgold.net

********************************************

Avery Dennison Corporation (NYSE:AVY) announced that Dean A. Scarborough, chairman, president and CEO, will present at 8:45 a.m. Central Time on May 10, 2011, at Robert W. Baird & Co.’s 2011 Growth Stock Conference in Chicago, Illinois. The presentation will be webcast live on Avery Dennison’s Investor Relations website (www.investors.averydennison.com). A replay will be available following the event. Institutional investors who would like a meeting with management should contact their R.W. Baird representative or Priscilla Silva of Avery Dennison at (626) 304-2165.

Avery Dennison Corporation produces pressure-sensitive materials, office products, tickets, tags, labels, and other converted products. The company operates in three segments: Pressure-sensitive Materials, Retail Information Services, and Office and Consumer Products.

************************************

Fidelity National Financial, Inc. (NYSE:FNF) a leading provider of title insurance, mortgage services, specialty insurance and information services, announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share. The dividend will be payable June 30, 2011, to stockholders of record as of June 16, 2011.

Fidelity National Financial, Inc., through its subsidiaries, provides title insurance, specialty insurance, claims management services, and information services in the United States.

************************************

Knight Transportation Inc. (NYSE:KNX) reported revenue and earnings for the first quarter ended March 31, 2011. For the quarter, total revenue increased 12.5% to $186.5 million from $165.7 million for the same quarter of 2010. Revenue before fuel surcharge increased 7.3% to $150.5 million compared to $140.3 million in the first quarter of 2010. Net income decreased to $9.9 million in the first quarter from $12.3 million for the same quarter of 2010 and net income per diluted share was $0.12, compared to $0.15 for the same quarter of 2010.

Knight Transportation, Inc., together with its subsidiaries, operates as a short to medium-haul truckload carrier of general commodities in the United States. The company was founded in 1989 and is headquartered in Phoenix, Arizona.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRME.OB).

Crown Equity Holdings, Inc. (CRWE)

Online marketing has become the storefront process for many of the world’s largest companies. In this current climate of connectivity, any company without an online presence may as well not exist. To many, it is by far the most important part of their marketing strategy.

Crown Equity Holdings Inc. offers internet media-driven advertising services, which covers and connects a range of marketing specialties, as well as search engine optimization for clients interested in online media awareness.

The online advertising gives your ads a wider coverage and this globally wider coverage helps in making your advertisements reach more audiences, which may ultimately help you in getting better results through your online advertising campaign.
Another main advantage of online advertising or marketing is the much affordable price when compared with the traditional advertising costs. With a much lesser cost you can advertise on the net for a wider range of audience and geographical locations.

Crown Equity Holdings, Inc. has creative resources to dramatically enhance one’s company’s corporate identity with its in-house advertising and name-branding services. This includes creating, designing, implementing logos, and other strategies which rapidly increase one’s company’s credibility and value. As many people know, brand strength is a good indicator of the strength of a company and its financial value.
Crown Equity Holdings, Inc. together with its digital network currently provides electronic media services specializing in online publishing, which brings together targeted audiences and advertisers.

Crown Equity Holdings, Inc.’s mission is to profitably disseminate a variety of information as a worldwide online media publisher in an environment that has a positive effect.

For more information about Crown Equity Holdings, Inc. visit its website
http://www.crownequityholdings.com

******************************

Power3 Medical Products, Inc (PWRME)

Breast cancer can have a number of symptoms but usually shows as a lump or thickening in the breast tissue (although most breast lumps are not cancerous). If cancer is detected at an early stage, it can be treated before it spreads to nearby parts of the body.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).
There are several different types of breast cancer, which can develop in different parts of the breast. Breast cancer is often divided into non-invasive and invasive types.

Non-invasive breast cancer: Non-invasive breast cancer is also known as cancer or carcinoma in situ, or pre-cancerous cells.

Invasive breast cancer: Invasive cancer has the ability to spread outside the breast, although this does not mean it necessarily has spread. The most common form of breast cancer is invasive ductal breast cancer, which develops in the cells that line the breast ducts.

Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of product NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

BC-SeraPro™ is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.

For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com

*****************************************

ITT Corporation (NYSE:ITT) will release its first-quarter 2011 financial results at 7:00 a.m. EDT, Friday, April 29, 2011. At 9:00 a.m. EDT, senior management will review financial and operating results, comment on current conditions and answer questions during an investor briefing. The briefing can be monitored live by calling +1 (706) 643-7542 (ID#: 57668879) or at the following address on the company’s website: www.itt.com/investors. A replay of the briefing will be available on the website and telephonically until Friday, May 6, 2011 at 6:00 p.m. The telephone replay is available by calling +1 (706) 645-9291 (ID#: 57668879).

ITT Corporation designs, manufactures, and sells a range of engineered products, and provides related services worldwide. The company was founded in 1920 and is based in White Plains, New York.

*****************************************

Holly Corporation (NYSE:HOC) plans to announced results for the quarter ended March 31, 2011 on May 5, 2011, before the opening of trading on the NYSE. The company has scheduled a webcast conference on May 5, 2011 at 4:00PM Eastern time to discuss financial results. An audio archive of this webcast will be available using the above noted link through May 18, 2011.
Holly Corporation, together with its subsidiaries, operates as a petroleum refiner in the United States. Holly Corporation was founded in 1947 and is based in Dallas, Texas.

*****************************************

Invesco Mortgage Capital Inc. (NYSE:IVR) will announced its first quarter 2011 results on Tuesday, May 10, 2011 at 8:30 am ET. Scheduled to speak are Richard King, President and Chief Executive Officer; John Anzalone, Chief Investment Officer; and Donald Ramon, Chief Financial Officer.

Invesco Agency Securities Inc. operates as a mortgage real estate investment trust. The company was founded in 2008 and is based in Atlanta, Georgia.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRME.OB).

Power3 Medical Products, Inc (PWRME.OB)

BC-SeraPro™ of Power3 Medical Products is a proteomic test for the diagnosis of breast cancer. This test is designed to measure the quantitative expression level of 22 protein biomarkers in the serum that differentiate between breast cancer patients and control subjects. The level of the biomarkers from the patient’s serum sample is compared to the Power3 Medical Products’ patient database. Statistical analysis by linear discriminant function will analyze the biomarker levels of the patient sample and assign a probability score for the diagnosis of the patient sample. Probability score is ranged from 0.0 to 1.0. Results of the BC-SeraPro™ test should not be considered a standalone diagnosis nor a guarantee and is intended to be used in conjunction with mammography and other accepted modalities.

Breast cancer is cancer that forms in the cells of the breasts. Breast cancer can occur in both men and women, but it’s far more common in women. After skin cancer, breast cancer is the most common cancer diagnosed in women in the United States. But breast cancer rates have fallen in recent years, though doctors aren’t certain why. Still, for many women, breast cancer is the disease they fear most.

Breast cancer can have a number of symptoms but usually shows as a lump or thickening in the breast tissue (although most breast lumps are not cancerous). If cancer is detected at an early stage, it can be treated before it spreads to nearby parts of the body.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual’s proteins to detect the presence of disease, a patient’s disease progression, a patient’s response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.

For more information about Power3 Medical Products, Inc. please visit http://www.power3medical.com.

***************************************

Majestic Gold Corp. (MJS.V)

Of all the minerals mined from the Earth, none is more useful than gold. Its usefulness is derived from a diversity of special properties. Gold conducts electricity, does not tarnish, is very easy to work, can be drawn into wire, can be hammered into thin sheets, alloys with many other metals, can be melted and cast into highly detailed shapes, has a wonderful color and a brilliant luster. Gold is a memorable metal that occupies a special place in the human mind.

Majestic Gold Corp. engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.

Gold is used as a drug to treat a small number of medical conditions. Injections of weak solutions of sodium aurothiomalate or aurothioglucose are sometimes used to treat rheumatoid arthritis. Particles of a radioactive gold isotope are implanted in tissues to serve as a radiation source in the treatment of certain cancers.

Majestic Gold Corp. announced that Wardrop, A Tetra Tech Company, (”Wardrop”) has completed and delivered a positive Preliminary Assessment (”PA” or “Preliminary Assessment”) for the Songjiagou Gold Project located in Shandong Province, People’s Republic of China.
Highlights are as follows:

– Net Present Value of US $525 million using a 10% discount rate.
– Internal Rate of Return of 78.6%.
– Payback in 1.4 years
– Total gold production of 2.324 million ounces (average 105,645 oz/yr) for life-of-mine
– Life-of-Mine strip ratio 1.87: 1 (waste to ore)
– Mine-Life of 22 years.

The Preliminary Assessment provided by Wardrop has exceeded their expectations and would form the basis for their continued development of the Songjiagou project.

For more information about Majestic Gold Corp. visit its website: http://www.majesticgold.net

*************************************

ULURU Inc. (AMEX:ULU) announced, in compliance with NYSE Amex listing regulations (Company Guide Rule 610(b)), that its audited financial statements for the fiscal year ended December 31, 2010, included in the Company’s Annual Report on Form 10-K, filed on March 31, 2011, contained a going concern qualification from its independent registered auditing firm, Lane Gorman Trubitt, PLLC. This announcement does not represent any change or amendment to the company’s financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2010.

ULURU Inc., a pharmaceutical company, engages in the research, development, and commercialization of wound care and muco-adhesive film products in the United States and internationally.

******************************************

Northgate Minerals Corp. (AMEX:NXG) provided an update on construction activities for its 100% owned Young-Davidson project located beside the town of Matachewan, Ontario, 60 kilometres (”km”) west of Kirkland Lake. The company’s is also pleased to report that follow-up drilling on the YD West zone continues to return positive results. With current proven and probable gold reserves totalling over 2.8 million ounces(1), the Young-Davidson mine is targeting start-up of production in late Q1 2012. The mine is expected to generate an average of 180,000 ounces of gold annually over an initial 15-year mine life.

Northgate Minerals Corporation, together with its subsidiaries, engages in mining, exploring, developing, and processing gold and copper deposits. Its principal producing assets include 100% interests in the Fosterville and Stawell Gold mines in Australia; and the Kemess South mine in Canada.

******************************************

Sulphco Inc. (AMEX:SUF) announced that it was implementing a substantial reduction in its workforce by April 30, 2011. The employees affected by the workforce reduction are primarily comprised of laboratory support and administrative personnel. In addition, the Company’s Board of Directors has instructed the management team and its advisors to pursue all potential strategic alternatives to obtain value for its shareholders.

SulphCo, Inc., an energy technology company, focuses on the development and commercialization of an oxidative desulfurization (ODS) process for crude oil products, crude oils, natural gasoline, and condensate streams.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRME.OB).